Literature DB >> 27215220

Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population.

Judith Sánchez-Manubens1,2, Jordi Antón3, Rosa Bou3, Estíbaliz Iglesias3, Joan Calzada-Hernandez3, Sergi Borlan3, Clara Gimenez-Roca3, Josefa Rivera4.   

Abstract

Kawasaki disease is an acute self-limited systemic vasculitis common in childhood. Intravenous immunoglobulin (IVIG) is an effective treatment, and it reduces the incidence of cardiac complications. Egami score has been validated to identify IVIG non-responder patients in Japanese population, and it has shown high sensitivity and specificity to identify these non-responder patients. Although its effectiveness in Japan, Egami score has shown to be ineffective in non-Japanese populations. The aim of this study was to apply the Egami score in a Western Mediterranean population in Catalonia (Spain). Observational population-based study that includes patients from all Pediatric Units in 33 Catalan hospitals, both public and private management, between January 2004 and March 2014. Sensitivity and specificity for the Egami score was calculated, and a logistic regression analysis of predictors of overall response to IVIG was also developed. Predicting IVIG resistance with a cutoff for Egami score ≥3 obtained 26 % sensitivity and 82 % specificity. Negative predictive value was 85 % and positive predictive value 22 %. This low sensitivity implies that three out of four non-responders will not be identified by the Egami score. Besides, logistic regression models did not found significance for the use of the Egami score to predict IVIG resistance in Catalan population although having an area under the ROC curve of 0.618 (IC 95 % 0.538-0.698, p < 0.001). Although regression models found an area under the ROC curve >0.5 to predict IVIG resistance, the low sensitivity excludes the Egami score as a useful tool to predict IVIG resistance in Catalan population.

Entities:  

Keywords:  Coronary aneurism; Egami score; Immunoglobulin resistance; Kawasaki disease

Mesh:

Substances:

Year:  2016        PMID: 27215220     DOI: 10.1007/s00296-016-3499-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation.

Authors:  Sophie Cohen; Carline E Tacke; Bart Straver; Natasja Meijer; Irene M Kuipers; Taco W Kuijpers
Journal:  Ann Rheum Dis       Date:  2012-06-11       Impact factor: 19.103

2.  Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.

Authors:  Mary Beth Son; Kimberlee Gauvreau; Jane C Burns; Elena Corinaldesi; Adriana H Tremoulet; Virginia E Watson; Annette Baker; David R Fulton; Robert P Sundel; Jane W Newburger
Journal:  J Pediatr       Date:  2010-12-03       Impact factor: 4.406

3.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

4.  Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.

Authors:  Lynn A Sleeper; L Luann Minich; Brian M McCrindle; Jennifer S Li; Wilbert Mason; Steven D Colan; Andrew M Atz; Beth F Printz; Annette Baker; Victoria L Vetter; Jane W Newburger
Journal:  J Pediatr       Date:  2010-12-18       Impact factor: 4.406

5.  Predicting IVIG resistance in UK Kawasaki disease.

Authors:  Sarah Davies; Natalina Sutton; Sarah Blackstock; Stuart Gormley; Clive J Hoggart; Michael Levin; Jethro A Herberg
Journal:  Arch Dis Child       Date:  2015-02-10       Impact factor: 3.791

6.  Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.

Authors:  Rohit S Loomba; Alexander Raskin; Todd M Gudausky; Edward Kirkpatrick
Journal:  Am J Ther       Date:  2016 Nov/Dec       Impact factor: 2.688

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

9.  Epidemiology and risk factors for coronary artery abnormalities in children with complete and incomplete Kawasaki disease during a 10-year period.

Authors:  Georgia Giannouli; Chryssa Tzoumaka-Bakoula; Ioannis Kopsidas; Paraskevi Papadogeorgou; George P Chrousos; Athanasios Michos
Journal:  Pediatr Cardiol       Date:  2013-03-06       Impact factor: 1.655

Review 10.  Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome.

Authors:  Donato Rigante; Laura Andreozzi; Michele Fastiggi; Benedetta Bracci; Marco Francesco Natale; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-02-24       Impact factor: 5.923

View more
  13 in total

1.  Risk scores for Kawasaki disease, a management tool developed by the KAWA-RACE cohort.

Authors:  Carlos D Grasa; Elisa Fernández-Cooke; Sara Domínguez-Rodríguez; Javier Aracil-Santos; Ana Barrios Tascon; Judith Sánchez-Manubens; Beatriz Mercader; Jordi Antón; Esmeralda Nuñez; Enrique Villalobos; Matilde Bustillo; Marisol Camacho; Manuel Oltra Benavent; Gemma Giralt; Ana Maria Bello Naranjo; Beatriz Rocandio; Cristina Calvo
Journal:  Clin Rheumatol       Date:  2022-08-08       Impact factor: 3.650

Review 2.  Dissecting Kawasaki disease: a state-of-the-art review.

Authors:  S M Dietz; D van Stijn; D Burgner; M Levin; I M Kuipers; B A Hutten; T W Kuijpers
Journal:  Eur J Pediatr       Date:  2017-06-27       Impact factor: 3.183

3.  The role of age-specific N-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: a prospective cohort study.

Authors:  Shuran Shao; Chunyan Luo; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2019-09-18       Impact factor: 3.054

4.  A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: a retrospective study on 5277 patients.

Authors:  Xu-Hai Tan; Xiao-Wei Zhang; Xiao-Yun Wang; Xiang-Qian He; Chu Fan; Tie-Wei Lyu; Jie Tian
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

5.  C-Reactive Protein to Albumin Ratio for Predicting Coronary Artery Lesions and Intravenous Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Chih-Min Tsai; Hong-Ren Yu; Kuo-Shu Tang; Ying-Hsien Huang; Ho-Chang Kuo
Journal:  Front Pediatr       Date:  2020-11-25       Impact factor: 3.418

6.  Comparison of Machine Learning Models for Prediction of Initial Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease.

Authors:  Yasutaka Kuniyoshi; Haruka Tokutake; Natsuki Takahashi; Azusa Kamura; Sumie Yasuda; Makoto Tashiro
Journal:  Front Pediatr       Date:  2020-12-03       Impact factor: 3.418

7.  Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.

Authors:  Yukako Yoshikane; Yoshiaki Okuma; Tatsuki Miyamoto; Junichi Hashimoto; Ryuji Fukazawa; Taichi Kato; Atsuhito Takeda; Kenji Suda; Takeji Matsushita; Michiaki Hiroe; Kyoko Imanaka-Yoshida
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-05       Impact factor: 3.054

8.  Usefulness of Kawasaki disease risk scoring systems to the Turkish population.

Authors:  Kazım Öztarhan; Yusuf Ziya Varlı; Nuray Aktay Ayaz
Journal:  Anatol J Cardiol       Date:  2020-08       Impact factor: 1.596

9.  Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease.

Authors:  Maryam Piram; Martha Darce Bello; Stéphanie Tellier; Sylvie Di Filippo; Franck Boralevi; Fouad Madhi; Ulrich Meinzer; Rolando Cimaz; Celine Piedvache; Isabelle Koné-Paut
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

10.  Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.

Authors:  Ryusuke Ae; Joseph Y Abrams; Ryan A Maddox; Lawrence B Schonberger; Yosikazu Nakamura; Masanari Kuwabara; Nobuko Makino; Yuri Matsubara; Koki Kosami; Teppei Sasahara; Ermias D Belay
Journal:  J Am Heart Assoc       Date:  2020-08-19       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.